Radioguided surgery and systemic radionuclide therapy of neuroendocrine tumours.
Neuroendocrine tumours (NETs) may be fatal, though at a significantly slower pace than their exocrine counterparts. Nuclear medicine procedures for diagnosis and treatment of NETs are based on expression of somatostatin receptors. Radioguided surgery is a new method for diagnosing and treating many tumours and uses introperative gamma probes. The use and development of intraoperative gamma probes in the last 10 years has enabled the development of minimally invasive procedures in oncological surgery, with an improvement in both the survival rate and the quality of life. Systemic therapy with radiolabeled somatostatin analogues is a promising new tool in the management of patients with inoperable or metastatic NETs. In terms of tumour regression, the results obtained are encouraging.
Hodolic
Marina
M
Department of Nuclear Medicine, University Medical Centre of Ljubljana, Ljubljana, Slovenia.
Fettich
Jure
J
Marzola
Maria Cristina
MC
Tonini
Eugenia
E
Al-Nahhas
Adil
A
Rubello
Domenico
D
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D019060:Minimally Invasive Surgical Procedures; D018358:Neuroendocrine Tumors / Q000378:metabolism / Q000532:radiotherapy* / Q000601:surgery*; D019275:Radiopharmaceuticals / Q000627:therapeutic use*; D016634:Radiosurgery / Q000379:methods*; D018714:Radiotherapy, Adjuvant; D017481:Receptors, Somatostatin / Q000187:drug effects / Q000378:metabolism; D013004:Somatostatin / Q000031:analogs & derivatives / Q000627:therapeutic use*; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D019275:Radiopharmaceuticals; D017481:Receptors, Somatostatin; D013004:Somatostatin